Novel Biomarker Serum Calprotectin for Early Diagnosis of Diabetic Peripheral Neuropathy in Type 2 Diabetes Patients | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 30, Volume 82, Issue 2, January 2021, Page 379-385 PDF (529.28 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2021.144904 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Farid Fawzy Abd El-hafez; Ayman Abd-Elrahman Mohamed Nsr-Allah; Ahmed Kamal Abd Eljalil Mohamed; Azza Moustafa Ahmed; Amira Ahmed Mahmoud 
| ||||
| Abstract | ||||
| Background: Calprotectin was identified as an endogenous activator of Toll-like receptor 4 (TLR4) and as receptor for advanced glycation end product (RAGE). Elevated plasma levels of calprotectin have been reported in a variety of chronic inflammatory conditions. Elevated calprotectin levels have been reported to predict microvascular alterations in type 2 diabetes (T2DM) patients. Objective: To make an up to date review of serum level of calprotectin as a predictor for early diagnosis of peripheral neuropathy in type 2 diabetes patients. Patients and methods: A total number of 90 subjects were included in the study after fulfillment of the inclusion and exclusion criteria. Calprotectin was measured for all the 90 subjects. Results: Serum calprotectin levels were significantly higher in group III “diabetics with neuropathy” compared to group II “diabetics without neuropathy “and group I “healthy controls”. Conclusion: High levels of calprotectin were detected in type 2 diabetic patients with peripheral neuropathy. | ||||
| Keywords | ||||
| Calprotectin; Diabetes mellitus; Neuroinflammation; Peripheral neuropathy | ||||
|
Statistics Article View: 324 PDF Download: 435 |
||||
